Amylin Pharmaceuticals, Inc., is a biopharmaceutical company engaged in the discovery, development, and commercialization of innovative medicines to improve the lives of people with diabetes, obesity, and cardiovascular disease. Amylin challenges conventional thinking to create innovative approaches to the discovery development,

and commercialization of novel therapies.